Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial

BACKGROUND: Up to 20% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis (BM), for which the current standard of care is radiation therapy with or without surgery. There are no prospective data on the safety of stereotactic radiosurgery (SRS) concurrent with immune checkpoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Altan, Mehmet, Wang, Yan, Song, Juhee, Welsh, James, Tang, Chad, Guha-Thakurta, Nandita, Blumenschein, George R, Carter, Brett W, Wefel, Jeffrey S, Ghia, Amol J, Yeboa, Debra N, McAleer, Mary Frances, Chung, Caroline, Woodhouse, Kristina D, McGovern, Susan L, Wang, Chenyang, Kim, Betty Y S, Weinberg, Jeffrey S, Briere, Tina M, Elamin, Yasir Y, Le, Xiuning, Cascone, Tina, Negrao, Marcelo V, Skoulidis, Ferdinandos, Ferrarotto, Renata, Heymach, John V, Li, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335483/
https://www.ncbi.nlm.nih.gov/pubmed/37402581
http://dx.doi.org/10.1136/jitc-2023-006871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335483/
https://www.ncbi.nlm.nih.gov/pubmed/37402581
http://dx.doi.org/10.1136/jitc-2023-006871

Ejemplares similares